General | Pacira BioSciences, Inc.

Skip to main navigation

Share your story
Sustainability
Partnerships
News
Medical Information

Company
Therapies
Innovation
Patients
Careers
Investors

Share your story
Sustainability
Partnerships
News
Medical Information

Search

code

General

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Read more about Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Read more about Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Read more about Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Read more about Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

Read more about Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Joins Life Science Cares as National Corporate Partner

Read more about Pacira BioSciences Joins Life Science Cares as National Corporate Partner

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Read more about Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Pagination

Page 1
Next page

Subscribe to General

Print Page
RSS Feeds
Email Alerts

Receive email alerts from Pacira

Sign up to automatically receive free Pacira BioSciences, Inc. financial information by email. Once signed up, you may choose from the following options;

Pacira BioSciences, Inc. SEC Filings Alert
Pacira BioSciences, Inc. News Alert

You may change your email options ar any time, or opt out if desired.

Sign up for email alerts

LinkedIn
X
YouTube
Instagram
Facebook
Share your story

EXPAREL^® (bupivacaine liposome injectable suspension), ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), and Pacira are registered trademarks of the respective subsidiaries of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.

Contact
Health Data Privacy Policy
Sitemap
Privacy Policy
Terms of Use
Accessibility Statement
Medical Information

© 2026 Pacira Pharmaceuticals, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. PP-MP-US-0289